focus -WSS

focus

author：comprehensive 2025-10-01 21:40:49 - browse：83787

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： House passes resolution saying Israel isn't a 'racist or apartheid state'

explore

hotspot

WSS

Johnson & Johnson sues to stop Medicare negotiation

Flagship, Pfizer team up in deal worth up to $7 billion

Results on Novartis prostate cancer therapy could expand its use

Roche drug slashes death risk in early

How AI can help patients find reliable information about doctors

Cassava Sciences’ Alzheimer’s clinical trials should be halted

hotspot

focus

hotspot

Bright Health sells Medicare Advantage business to Molina

Roivant's CEO is a star, but biotech's black hole persists

Novavax promises a turnaround & Lilly roils the obesity market

FDA clears Verve to begin U.S. study of gene

As demand for Covid shots wanes, Moderna seeks its next success

Smaller biotechs seek to piggyback on weight loss drug boom

After affirmative action ruling, medical educators look to 'holistic review'

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Hollywood unions extend contract negotiations for actors

ER docs worry over extreme heat as a 'mass casualty event'

focus

Johnson & Johnson sues to stop Medicare negotiation

A Theranos scientist

Biden administration sends mixed signals on US soldier who crossed into North Korea

STAT Summit: Ending the crisis of Black deaths in the U.S.

ER docs worry over extreme heat as a 'mass casualty event'

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

explore

hotspot

entertainment

hotspot